Table 1.
Patient baseline characteristics
| IBD all population | Treatment group | Placebo group | Adj.P | |
|---|---|---|---|---|
| Male, n, % | 36, 73.46 | 15, 71.4 | 21, 75 | 1 |
| Median Age, years | 51 (19‐73) | 51(19‐69) | 50(25‐73) | 1 |
| Median BMI | 24.12(16.04‐30.02) | 23.84 | 24.21 | 1 |
| Type of disease, n, % | CD, 19, 38.77 | 7 | 12 | 1 |
| Montreal classification UC, n, % | ||||
| E1 | 2, 6.6 | 1 | 1 | 1 |
| E2 | 13, 43.3 | 6 | 7 | |
| E3 | 15, 50 | 7 | 8 | |
| CD behavior, n, % | ||||
| B1 | 16, 84.2 | 4 | 12 | .08 |
| B2 | 3, 15.7 | 3 | — | |
| B3 | 0 | — | — | |
| Location, n, % | ||||
| L1 | 5, 26.3 | 3 | 2 | .48 |
| L2 | 5, 26.3 | — | 5 | |
| L3 | 9, 47.3 | 4 | 5 | |
| Endoscopic score | ||||
| Mayo score, n, % | ||||
| 0 | 14, 46.6 | 7 | 7 | 1 |
| 1 | 8, 26.6 | 4 | 4 | |
| 2 | 5, 16.6 | 3 | 2 | |
| 3 | 3, 10 | — | 3 | |
| SES‐CD, n, % | ||||
| 0‐2 | 9, 47.36 | 3 | 6 | 1 |
| 3‐6 | 7, 36.8 | 3 | 4 | |
| 7‐15 | 3, 15.7 | 1 | 2 | |
| >15 | 0 | — | — | |
| Previous surgery n (CD‐UC), % | 7, 31.5 | 6 (5‐1) | 1 (1‐0) | .12 |
| Smokers CD, UC | 3, 2 | 2 | 3 | 1 |
| Therapy | ||||
| Biologics n, % | 20, 40.8 | 8 | 12 | 1 |
| 5‐ASA n, % | 45, 91.8 | 20 | 25 | 1 |
| Probiotics(ECN) n, % | 4, 8.1 | 2 | 2 | 1 |
| Steroids n, % | 7, 14 | 1 | 6 | .84 |
| Immunosuppressant n, % | 6, 12.2 | 3 | 3 | 1 |
| PPI | 7, 14 | 1 | 6 | .84 |
Baseline characteristics of CD (n = 19) an UC (n = 30) patients allocated on the butyrose(treatment) or placebo groups. The adj.P‐value was calculated as described on the statistical data analysis.